MACK Overview
Upcoming Projects (MACK)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MACK)
-
Discussing the commercial experience of ONIVYDE (irinotecan liposome injection) in pancreatic cancer
Tickers: IPSEF, MACK, IPN.XPAR
Executed On: Nov 04, 2022 at 03:30 PM EDT
Expired Projects (MACK)
Upcoming & Overdue Catalysts (MACK)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (MACK)
-
Phase 2 data of MM-121 for Heregulin Positive Non-Small Cell Lung Cancer due 2H 2018
Ticker: MACK
Occurred on: Sep 06, 2018 -
Top-Line Phase 2 CARRIE Data Evaluating MM-141 in Front Line Pancreatic Cancer Due H2 2018 - Discontinued
Ticker: MACK
Occurred on: Jun 25, 2018 -
Merrimack Pharmaceuticals (MACK) initiates Phase 1 study of MM-310 in solid tumors, looking to extract appropriate dosage for Phase 2
Ticker: MACK
Occurred on: Mar 31, 2017 -
Merrimack (MACK) Terminates Phase 2 HERMIONE Trial Evaluating MM-302 in HER2-Positive Locally Advanced or Metastatic Breast Cancer
Ticker: MACK
Occurred on: Dec 21, 2016 -
Merrimack (MACK) Presents Final Phase 3 NAPOLI-1 Data Evaluating ONIVYDE in Pancreatic Cancer
Ticker: MACK
Occurred on: Oct 11, 2016 -
Phase 3 data of ONIVYDE for first line pancreatic due 1H 2017
Tickers: IPSEY, MACK
Occurred on: Oct 11, 2016 -
Merrimack Announces ONIVYDE Regimen for Pancreatic Cancer Receives Positive CHMP Opinion in European Union
Tickers: MACK, SHPG
Occurred on: Jul 25, 2016 -
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
Ticker: MACK
Occurred on: Jul 06, 2016
Strategic Initiatives (MACK)
-
Ipsen (IPSEY) Agrees to Acquire Some of Merrimack's (MACK) Oncology Assets, Including Pancreatic Cancer Drug Onivyde, For Up to $1 Billion
Tickers: MACK, IPSEY
Announcement Date: Jan 09, 2017
